USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line o...
Main Authors: | V. R. Mkrtchyan, L. V. Brylev, I. A. Shpak, A. M. Sergeev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2016-12-01
|
Series: | Неврология, нейропсихиатрия, психосоматика |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/681 |
Similar Items
-
The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01) -
Assessment of Total Side Effects of Oral Agents for the Treatment of Relapsing–Remitting Multiple Sclerosis Patients in Imam Khomeini Clinic in Hamadan
by: M Ghiasian, et al.
Published: (2023-12-01) -
Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01) -
Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach
by: Angelo Ghezzi
Published: (2024-06-01) -
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
by: Aliya Jaber, et al.
Published: (2023-02-01)